

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAMPC1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	OCT 04	Removal of Pre-IPC 8 data fields streamlines displays in USPATFULL, USPAT2, and USPATOLD.
NEWS	3	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
NEWS	4	OCT 06	Increase your retrieval consistency with new formats or for Taiwanese application numbers in CA/CAPLUS.
NEWS	5	OCT 21	CA/CAPLUS kind code changes for Chinese patents increase consistency, save time
NEWS	6	OCT 22	New version of STN Viewer preserves custom highlighting of terms when patent documents are saved in .rtf format
NEWS	7	OCT 28	INPADOCDB/INPAFAMDB: Enhancements to the US national patent classification.
NEWS	8	NOV 03	New format for Korean patent application numbers in CA/CAPLUS increases consistency, saves time.
NEWS	9	NOV 04	Selected STN databases scheduled for removal on December 31, 2010
NEWS	10	NOV 18	PROUSDDR and SYNTHLINE Scheduled for Removal December 31, 2010 by Request of Prous Science
NEWS	11	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching
NEWS	12	NOV 22	Enjoy a free month of INPADOCDB/INPAFAMDB SDIs!
NEWS	13	NOV 24	Search an additional 46,850 records with MEDLINE backfile extension to 1946
NEWS	14	DEC 14	New PNK Field Allows More Precise Crossover among STN Patent Databases
NEWS	15	DEC 18	ReaxysFile available on STN
NEWS	16	DEC 21	CAS Learning Solutions -- a new online training experience
NEWS	17	DEC 22	Value-Added Indexing Improves Access to World Traditional Medicine Patents in CAPLUS

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges

and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 19:32:56 ON 10 JAN 2011

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.23

0.23

FILE 'REGISTRY' ENTERED AT 19:33:14 ON 10 JAN 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JAN 2011 HIGHEST RN 1258835-38-9

DICTIONARY FILE UPDATES: 9 JAN 2011 HIGHEST RN 1258835-38-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10588754\_01102011\_1.str



chain nodes :

6

ring nodes :

1 2 3 4 5 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

1-6 2-7

ring bonds :

1-2 1-5 2-3 3-4 4-5 7-8 7-11 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17

exact/norm bonds :

1-2 1-5 1-6 2-3 2-7 3-4 4-5 7-8 7-11 8-9 9-10 10-11


normalized bonds :

12-13 12-17 13-14 14-15 15-16 16-17

Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom  
 Element Count :  
 Node 6: Limited  
 N,N3

L1 STRUCTURE UPLOADED

=> d  
 L1 HAS NO ANSWERS  
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam  
 SAMPLE SEARCH INITIATED 19:33:34 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 446456 TO ITERATE

100.0% PROCESSED 446456 ITERATIONS 4 ANSWERS  
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
 BATCH \*\*INCOMPLETE\*\*  
 PROJECTED ITERATIONS: 8890556 TO 8967684  
 PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=>  
 Uploading C:\Program Files\STNEXP\Queries\10588754\_01102011\_2.str



ring nodes :

```

1  2  3  4  5  6  7  8  9  10
chain bonds :
2-6
ring bonds :
1-2  1-5  2-3  3-4  4-5  6-7  6-10  7-8  8-9  9-10
exact/norm bonds :
1-2  1-5  2-3  2-6  3-4  4-5  6-7  6-10  7-8  8-9  9-10

```

```

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom


```

L3            STRUCTURE UPLOADED

```

=> d
L3 HAS NO ANSWERS
L3            STR

```



Structure attributes must be viewed using STN Express query preparation.

```

=> s l3 sam
SAMPLE SEARCH INITIATED 19:34:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 482625 TO ITERATE

```

```

100.0% PROCESSED 482625 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:   9612535 TO 9692465
PROJECTED ANSWERS:      124165 TO 133795

```

L4            50 SEA SSS SAM L3

```


=> e pyrrolidine/CN
E1          1  PYRROLIDIN-3-YLMETHYL METHANESULFONATE/CN
E2          1  PYRROLIDINAMINE, 1-(5-AMINO-2-FLUOROPHENYL)-N-METHYL-/CN
E3          1  --> PYRROLIDINE/CN
E4          1  PYRROLIDINE 1-(3-(P-BROMOPHENOXY)PROPYL)-/CN
E5          1  PYRROLIDINE 183B/CN
E6          1  PYRROLIDINE 253I/CN
E7          1  PYRROLIDINE DITHIOCARBAMIC ACID/CN
E8          1  PYRROLIDINE GLUTAMIC ACID SALT/CN
E9          1  PYRROLIDINE GREEN/CN
E10         1  PYRROLIDINE HEXAFLUOROPHOSPHATE/CN
E11         1  PYRROLIDINE M-TOLUATE/CN
E12         1  PYRROLIDINE NITROXIDE/CN

```

```
=> s e3
L5          1 PYRROLIDINE/CN
```

```
=> d str rsd
```

```
L5  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2011 ACS on STN
```



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

#### Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System Formula	Ring Identifier	RID Occurrence
EA	ES	SZ	RF	RID	Count
=====	+	=====	+	=====	+
C4N	NC4	5	C4N	16.136.1	1

```
=> e benzene/CN
```

```
E1          1  BENZENAMINIUM-15N, N,N-DIMETHYL-N-2-PROPYNYL-/CN
E2          1  BENZENAMINIUM-15N, N,N-DIMETHYL-N-2-PROPYNYL-, BROMIDE/CN
E3          1  --> BENZENE/CN
E4          1  BENZENE (93) ARBOROL/CN
E5          1  BENZENE (HOMOPOLYMER), BIS(2-(TRIETHOXSILYL)ETHYL)-/CN
E6          1  BENZENE 1,2,4-TRISPHOSPHATE/CN
E7          1  BENZENE 1,2-DIOXYGENASE/CN
E8          1  BENZENE 1,2-DIOXYGENASE FERREDOXIN PROTEIN (XANTHOMONAS AXON
OPODIS CITRI STRAIN 306 GENE BEDB)/CN
E9          1  BENZENE 1,2-DIOXYGENASE FERREDOXIN PROTEIN (XANTHOMONAS ORYZ
AE ORYZAE STRAIN KACC10331 GENE BEDB)/CN
E10         1  BENZENE 1,2-DIOXYGENASE FERREDOXIN PROTEIN (XANTHOMONAS ORYZ
AE ORYZAE STRAIN MAFF 311018 GENE XO01283)/CN
E11         1  BENZENE 1,2-DIOXYGENASE RIESKE IRON-SULFUR COMPONENT (LEPTOS
PIRA INTERROGANS ICTEROHAEMORRHAGIAE STRAIN 56601 GENE LA356
1)/CN
E12         1  BENZENE 1,2-DIOXYGENASE SYSTEM FERREDOXIN COMPONENT (LEPTOSP
IRA INTERROGANS COPENHAGENI STRAIN FIOCRUZ L1-130 GENE BEDB)
/CN
```

```
=> s e3
L6          1 BENZENE/CN
```

```
=> d str rsd
```

```
L6  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2011 ACS on STN
```



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

# Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System Formula	Ring Identifier	RID Occurrence
EA	ES	SZ	RF	RID	Count
C6	C6	6	C6	46.150.18	1

```
=> s 46.150.18/RID (P) 16.136.1/RID
      36828646 46.150.18/RID
      2845306 16.136.1/RID
L7      2020914 46.150.18/RID (P) 16.136.1/RID
```

=> d his

(FILE 'HOME' ENTERED AT 19:32:56 ON 10 JAN 2011)

FILE 'REGISTRY' ENTERED AT 19:33:14 ON 10 JAN 2011

```
L1      STRUCTURE UPLOADED
L2      4 S L1 SAM
L3      STRUCTURE UPLOADED
L4      50 S L3 SAM
          E PYRROLIDINE/CN
L5      1 S E3
          E BENZENE/CN
L6      1 S E3
L7      2020914 S 46.150.18/RID (P) 16.136.1/RID
```

```
=> s l1 sss sub=l7 sam
SAMPLE SUBSET SEARCH INITIATED 19:36:05 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 50354 TO ITERATE
```

```
100.0% PROCESSED 50354 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01
```

```
PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 993673 TO 1020487
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 3 TO 163
```

```
L8      3 SEA SUB=L7 SSS SAM L1
```

```
=> s l1 sss sub=l7 full
FULL SUBSET SEARCH INITIATED 19:36:10 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 1008281 TO ITERATE
```

```
94.9% PROCESSED 956905 ITERATIONS 65 ANSWERS
100.0% PROCESSED 1008281 ITERATIONS 65 ANSWERS
SEARCH TIME: 00.00.20
```

L9 65 SEA SUB=L7 SSS FUL L1

=> s 19 and caplus/lc  
73405355 CAPLUS/LC


L10 64 L9 AND CAPLUS/LC

=> s 19 not l10

L11 1 L9 NOT L10

=> d

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2011 ACS on STN  
RN 1244880-21-4 REGISTRY  
ED Entered STN: 03 Oct 2010  
CN Oxazolo[5,4-d]pyrimidine, 2,5-dimethyl-7-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)-1-pyrrolidinyl]- (CA INDEX NAME)  
MF C19 H18 N6 O2  
SR Chemical Library  
Supplier: ChemBridge Corporation  
LC STN Files: CHEMCATS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

=> file caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
233.26	233.49

FILE 'CAPLUS' ENTERED AT 19:36:47 ON 10 JAN 2011  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jan 2011 VOL 154 ISS 3  
FILE LAST UPDATED: 9 Jan 2011 (20110109/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

CAPLUS now includes complete International Patent Classification (IPC)  
reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> d his

(FILE 'HOME' ENTERED AT 19:32:56 ON 10 JAN 2011)

FILE 'REGISTRY' ENTERED AT 19:33:14 ON 10 JAN 2011

L1 STRUCTURE UPLOADED  
L2 4 S L1 SAM  
L3 STRUCTURE UPLOADED  
L4 50 S L3 SAM  
E PYRROLIDINE/CN  
L5 1 S E3  
E BENZENE/CN  
L6 1 S E3  
L7 2020914 S 46.150.18/RID (P) 16.136.1/RID  
L8 3 S L1 SSS SAM SUB=L7  
L9 65 S L1 SSS FULL SUB=L7  
L10 64 S L9 AND CAPLUS/LC  
L11 1 S L9 NOT L10

FILE 'CAPLUS' ENTERED AT 19:36:47 ON 10 JAN 2011

=> s l10

L12 9 L10

=> d l12 ibib gi abs hitstr 1-9

L12 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:524228 CAPLUS

DOCUMENT NUMBER: 150:472728

TITLE: Preparation of 1,2,4-triazole carboxylic acid  
derivatives as modulators of mGluR5

INVENTOR(S): Granberg, Kenneth; Slassi, Abdelmalik; Stefanac,  
Tomislav; Waallberg, Andreas

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 46pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2009054787	A1	20090430	WO 2008-SE51190	20081023
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,			



PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,  
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM



US 20090111811 A1 20090430 US 2008-258022 20081024

PRIORITY APPLN. INFO.: US 2007-982949P P 20071026



ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 150:472728; MARPAT 150:472728

GI



GI



AB The title compds. I [R1 = H, Me, halo, CN; R2 = H or F; R3 = alkyl or cyclopropyl; R4 = NR5R9, OH, alkoxy; R5 = H or alkyl; R9 = H or alkyl; X = isoxazole, triazole, tetrazole, etc.; Y = pyrrolidine, morpholine], useful as modulators of mGluR5, were prepared E.g., a multi-step synthesis of (2R)-II, starting from tert-Bu (2R)-2-formylpyrrolidine-1-carboxylate, was given. Compound (2R)-II showed IC50 of 11 nM against human mGluR5d in the FLIPR assay. Pharmaceutical compns. comprising compound I, alone or in combination with other therapeutic agent, are disclosed.


IT 1147111-53-2P 1147111-55-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,2,4-triazole carboxylic acid derivs. as modulators of mGluR5)

RN 1147111-53-2 CAPLUS

CN Benzamide, 4-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1147111-55-4 CAPLUS

CN Benzamide, 4-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-

4-methyl-4H-1,2,4-triazol-3-yl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




```

IT      1147111-60-1P      1147111-62-3P
      RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
      (Reactant or reagent)
      (preparation of 1,2,4-triazole carboxylic acid derivs. as modulators of
      mGluR5)
RN      1147111-60-1      CAPLUS
CN      Benzoic acid, 4-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-
      pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-, methyl ester (CA INDEX
      NAME)


```

Absolute stereochemistry.



RN	11471111-62-3	CAPLUS
CN	Benzoic acid, 4-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)	

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:524183 CAPLUS

DOCUMENT NUMBER: 150:472725

TITLE: Preparation of 1,2,4-triazole aryl N-oxides derivatives as modulators of mGluR5

INVENTOR(S): Granberg, Kenneth; Waallberg, Andreas

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 51pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009054786	A1	20090430	WO 2008-SE51189	20081023
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20090111854	A1	20090430	US 2008-258151	20081024

PRIORITY APPLN. INFO.: US 2007-982939P P 20071026



ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 150:472725; MARPAT 150:472725

GI



GI



AB The title compds. I [R1 = Me, halo, CN; R2 = H or F; X = isoxazole, triazole, tetrazole, etc.; Y = triazolylpiperidinyl, triazolylpyrrolidinyl, triazolylaminoalkyl, etc.], useful as modulators of mGluR5, were prepared. Thus, treating N-{(1S)-1-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethyl}-N,4-dimethyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-amine with hydrogen peroxide afforded 58% (1S)-II which showed IC50 of 81 nM against human mGluR5d in FLIPR assay. Pharmaceutical compns. comprising compound I, alone or in combination with other therapeutic agent, are disclosed.

IT 1147105-72-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,2,4-triazole aryl N-oxides derivs. as modulators of mGluR5)

RN 1147105-72-3 CAPLUS


CN Pyridine, 3-[5-[(2R)-2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-, 1-oxide (CA INDEX NAME)

Absolute stereochemistry.



IT 1147105-73-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of 1,2,4-triazole aryl N-oxides derivs. as modulators of  
mGluR5)  
RN 1147105-73-4 CAPLUS  
CN Pyridine, 3-[5-[ (2R)-2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-1-  
pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L12 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN  
ACCESSION NUMBER: 2009:523972 CAPLUS  
DOCUMENT NUMBER: 150:447958  
TITLE: Aminopyridine derivatives as modulators of mGluR5 and  
their preparation and use in the treatment of diseases  
INVENTOR(S): Granberg, Kenneth; Holm, Bjoern  
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.  
SOURCE: PCT Int. Appl., 48pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009054792	A1	20090430	WO 2008-SE51195	20081023
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090111823	A1	20090430	US 2008-258165	20081024
PRIORITY APPLN. INFO.:			US 2007-982968P	P 20071026
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 150:447958				

GI



GI




AB The invention is directed to compds. of formula I as modulators of metabotropic glutamate receptors (mGluRs) and to a process for their preparation, their use in therapy and pharmaceutical compns. comprising the novel compds. Compds. of formula I wherein R1 is Me, halo, and CN; R2 is H and F; R3 is C1-3 alkyl and cyclopropyl; X is isoxazolyl, oxadiazolyl, triazolyl, and tetrazolyl; Y is aminopyridinyl; and pharmaceutically acceptable salts, hydrates, isoforms, tautomers, and enantiomers thereof, are claimed. Example compound II was prepared by cyclocondensation with Me 2-[5-(3-chlorophenyl)isoxazol-3-yl]-N-methylpyrrolidine-1-carbimidothioate with 6-dimethylaminonicotinohydrazide. All the invention compds. were evaluated for their mGluR5 modulatory activity (some data given).

IT 1146111-50-3P 1146111-51-4P 1146111-53-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aminopyridine derivs. as modulators of mGluR5 useful in the treatment of diseases)

RN 1146111-50-3 CAPLUS

CN 2-Pyridinamine, 5-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 1146111-51-4 CAPLUS



CN 2-Pyridinamine, 5-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 1146111-53-6 CAPLUS

CN 2-Pyridinamine, 5-[4-methyl-5-[(2R)-2-(5-phenyl-3-isoxazolyl)-1-pyrrolidinyl]-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:523963 CAPLUS

DOCUMENT NUMBER: 150:472724

TITLE: Preparation of 1,2,3-triazole pyrrolidine derivatives as modulators of mGluR5

INVENTOR(S): Bratt, Emma; Granberg, Kenneth

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 49pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009054789	A1	20090430	WO 2008-SE51192	20081023
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,				

CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,  
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,  
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,  
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,  
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


US 20090111822 A1 20090430 US 2008-258161 20081024

PRIORITY APPLN. INFO.: US 2007-982954P P 20071026


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 150:472724

GI




I




II

GI



I



II

AB The title compds. I [R1 = Me, halo, CN; R2 = H or F; R3 = alkyl or cyclopropyl; X = triazole; Z = pyrimidinyl, pyrazinyl, pyridazinyl, etc.; R6 = H, F, alkyl, etc.], useful as modulators of mGluR5, were prepared E.g., a multi-step synthesis of (2R)-II, starting from tert-Bu (2R)-2-ethynylpyrrolidine-1-carboxylate and 3-chloriodobenzene, was given. Compound (2R)-II showed IC50 of 58 nM against human mGluR5d in FLIPR assay. Pharmaceutical compns. comprising compound I, alone or in combination with other therapeutic agent, are disclosed.

IT 1147101-32-3P 1147101-33-4P 1147101-34-5P  
1147101-35-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,2,3-triazole pyrrolidine derivs. as modulators of mGluR5)

RN 1147101-32-3 CAPLUS

CN Pyridine, 4-[5-[(2R)-2-[1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1147101-33-4 CAPLUS

CN Pyridine, 3-[5-[(2R)-2-[1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl]-1-

pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1147101-34-5 CAPLUS

CN Pyridazine, 4-[5-[(2R)-2-[1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1147101-35-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-[5-[(2R)-2-[1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS

L12 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:1359925 CAPLUS

DOCUMENT NUMBER: 149:556642

TITLE: Preparation of  
5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one  
derivatives as P2X3 receptor antagonists for treating  
especially pain

INVENTOR(S): Bayrakdarian, Malken; Buon, Christophe; Cantin,  
Louis-David; Hu, Yun-Jin; Luo, Xuehong; Santhakumar,  
Vijayaratnam; Tomaszewski, Mirosław

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 473pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008136756	A1	20081113	WO 2008-SE50525	20080507
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20090099195	A1	20090416	US 2008-115169	20080505
AU 2008246351	A1	20081113	AU 2008-246351	20080507
CA 2686707	A1	20081113	CA 2008-2686707	20080507
AR 66475	A1	20090819	AR 2008-101934	20080507
KR 2010017688	A	20100216	KR 2009-7025526	20080507
EP 2155751	A1	20100224	EP 2008-767136	20080507
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			
JP 2010526138	T	20100729	JP 2010-507363	20080507
IN 2009DN06714	A	20100618	IN 2009-DN6714	20091021
MX 2009011997	A	20091119	MX 2009-11997	20091105
CN 101687875	A	20100331	CN 2008-80023961	20100108
PRIORITY APPLN. INFO.:			US 2007-916588P	P 20070508
			WO 2008-SE50525	W 20080507



ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 149:556642; MARPAT 149:556642

GI




GI



AB The invention is related to the preparation of pyrrolopyrimidinones I [R1, R2 = independently H, (un)substituted carbonylalkyl, cycloalkyl fused with a Ph, alkyl, etc.; or NR1R2 = (un)substituted heterocyclyl; R3, R4 = H, (un)substituted alk(en)yl, cycloalkyl, aryl, etc.; or NR3R4 = (un)substituted heterocyclyl; R5 = H, (un)substituted cyclo/alkyl, heterocyclyl, aryl; provided that at least one of R1-4 is not H; with the exception of specified compds.] and their pharmaceutically acceptable salts, diastereomers, enantiomers, and their mixts. as P2X3 purinoceptor

receptor antagonists useful in the management of pain. Thus, cyclization of orotic acid with formaldehyde, treatment of fuoropyrimidinone with isopropylamine hydrochloride, chlorination of dihydroxypyrrolopyrimidinone, followed by a first amination with N-(4-fluorobenzyl)cyclopentanamine and a second amination with 1-acetylpiperazine gave II as a trifluoroacetate. I displayed antagonistic activity at human P2X3 and rat P2X2/3 receptors. Pyrrolopyrimidinones I are useful for treating pain, overactive bladder, anxiety, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, and cardiovascular disorders (no data).

IT 1079658-69-7P, 4-(4-Acetylpiperazin-1-yl)-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)pyrrolidin-1-yl]-8-propan-2-yl-3,5,8-triazabicyclo[4.3.0]nona-1,3,5-trien-7-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of pyrrolopyrimidinones as P2X3 receptor antagonists)  
 RN 1079658-69-7 CAPLUS  
 CN 7H-Pyrrolo[3,4-d]pyrimidin-7-one, 2-(4-acetyl-1-piperazinyl)-5,6-dihydro-6-(1-methylethyl)-4-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)-1-pyrrolidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)  
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN  
 ACCESSION NUMBER: 2007:1271499 CAPLUS  
 DOCUMENT NUMBER: 147:522250  
 TITLE: Preparation of trisubstituted triazoles as mGluR5 modulators. I.  
 INVENTOR(S): Wallberg, Andreas; Nilsson, Karolina; Holm, Bjorn; Nagard, Mats; Granberg, Kenneth; Slassi, Abdelmalik; Edwards, Louise; Isaac, Methvin; Xin, Tao; Stefanac, Tomislav  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.  
 SOURCE: U.S. Pat. Appl. Publ., 49 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070259862	A1	20071108	US 2007-790417	20070425

US 7678796	B2	20100316		
AU 2007248288	A1	20071115	AU 2007-248288	20070425
CA 2650114	A1	20071115	CA 2007-2650114	20070425
WO 2007130820	A2	20071115	WO 2007-US67367	20070425
WO 2007130820	A3	20080313		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AR 60651	A1	20080702	AR 2007-101781	20070425
EP 2027120	A2	20090225	EP 2007-761248	20070425

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

JP 2009536209	T	20091008	JP 2009-509953	20070425
IN 2008DN08841	A	20090327	IN 2008-DN8841	20081021
MX 2008013835	A	20081110	MX 2008-13835	20081028
NO 2008004850	A	20081202	NO 2008-4850	20081118
KR 2009009952	A	20090123	KR 2008-7029720	20081204
CN 101506202	A	20090812	CN 2007-80025294	20090104

PRIORITY APPLN. INFO.: US 2006-797659P P 20060505  
WO 2007-US67367 W 20070425

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): MARPAT 147:522250  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The present invention is directed to novel compds. I [R1 = Me, halo or CN; R2 = H or F; R3 = H, F or alkyl; R4 = alkyl, cyclopropyl; Y = a bond, O, S, SO, etc.; X = isoxazole, tetrazole, etc.; Z = pyrimidinyl, pyrazinyl, pyridazinyl, etc.; R7 = H, F or alkyl], to a process for their preparation, their use in therapy and pharmaceutical compns. comprising the novel compds. Thus, heating 2-[5-(3-chlorophenyl)isoxazol-3-yl]piperidine-1-carbothioic acid methylamide with 2,6-dimethoxypyrimidine-4-carboxylic acid hydrazide in iso-PrOH in a sealed vial at 100°C for 5 days afforded 24% II. Generally, compds. I were active with IC50 values less than 10000 nM in assay for mGluR5.

IT	956385-42-5P	956385-43-6P	956385-44-7P
	956385-45-8P	956385-46-9P	956385-47-0P
	956385-48-1P	956385-49-2P	956385-50-5P
	956385-52-7P	956385-54-9P	956385-56-1P
	956385-57-2P	956385-58-3P	956385-60-7P
	956385-61-8P	956385-62-9P	956385-64-1P



956385-66-3P	956385-67-4P	956385-68-5P
956385-69-6P	956385-70-9P	956385-71-0P
956385-72-1P	956385-73-2P	956385-74-3P
956385-75-4P	956385-76-5P	956385-77-6P
956385-78-7P	956385-79-8P	956385-80-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of trisubstituted triazoles as mGluR5 modulators)

RN 956385-42-5 CAPLUS

CN Benzonitrile, 3-[3-[(2R)-1-[4-methyl-5-(5-pyrimidinyl)-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-5-isoxazolyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-43-6 CAPLUS

CN Benzonitrile, 3-[5-[(2R)-1-[4-methyl-5-(2-pyrazinyl)-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-2H-tetrazol-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-44-7 CAPLUS

CN Benzonitrile, 3-[3-[(2R)-1-[4-methyl-5-(2-pyrazinyl)-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-5-isoxazolyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-45-8 CAPLUS

CN Pyrimidine, 5-[5-[(2R)-2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-46-9 CAPLUS

CN 2(1H)-Pyridinone, 4-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 956385-47-0 CAPLUS

CN 2(1H)-Pyridinone, 5-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-1-methyl- (CA INDEX NAME)

pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-48-1 CAPLUS


CN Pyridazine, 4-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 956385-49-2 CAPLUS

CN Pyrimidine, 5-[5-[2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 956385-50-5 CAPLUS  
CN Pyrazine, 2-[5-[(2S)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 956385-52-7 CAPLUS  
CN 2(1H)-Pyridinone, 4-[5-[(2R)-2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 956385-54-9 CAPLUS  
CN 2(1H)-Pyridinone, 4-[5-[(2R)-2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-56-1 CAPLUS

CN 2(1H)-Pyridinone, 4-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-57-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-58-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-60-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-[5-[(2R)-2-[5-(3-fluorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-61-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[5-[(2R)-2-[5-(3-fluorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-62-9 CAPLUS

CN 2(1H)-Pyridinone, 1-methyl-4-[4-methyl-5-[(2R)-2-[5-(3-methylphenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-64-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-[4-methyl-5-[(2R)-2-[5-(3-methylphenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 956385-66-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-methyl-5-[4-methyl-5-[(2R)-2-[5-(3-methylphenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 956385-67-4 CAPLUS

CN 2(1H)-Pyridinone, 4-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-1,6-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-68-5 CAPLUS

CN 2(1H)-Pyridinone, 4-[4-methyl-5-[(2R)-2-[5-(3-methylphenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4H-1,2,4-triazol-3-yl]-1,6-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-69-6 CAPLUS

CN 4(3H)-Pyrimidinone, 6-[4-methyl-5-[(2R)-2-[5-(3-methylphenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-70-9 CAPLUS

CN Pyridazine, 4-[5-[(2R)-2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 956385-71-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-

pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-72-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-[5-[(2R)-2-[5-(3-fluorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-73-2 CAPLUS

CN 4(3H)-Pyrimidinone, 6-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-74-3 CAPLUS

CN 2(1H)-Pyridinone, 6-[5-[(2R)-2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-75-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-[5-[(2R)-2-[5-(2,5-difluorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-76-5 CAPLUS

CN 4(3H)-Pyrimidinone, 6-[5-[(2R)-2-[5-(5-chloro-2-fluorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-77-6 CAPLUS

CN 2(1H)-Pyridinone, 4-[5-[(2R)-2-[5-(5-chloro-2-fluorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-78-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-[5-[(2R)-2-[5-(5-chloro-2-fluorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-79-8 CAPLUS

CN 2(1H)-Pyridinone, 4-[5-[(2R)-2-[5-(2-fluoro-5-methylphenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956385-80-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-[5-[(2R)-2-[5-(2-fluoro-5-methylphenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD  
(8 CITINGS)  
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:1270611 CAPLUS

DOCUMENT NUMBER: 147:522248

TITLE: Preparation of trisubstituted triazoles as mGluR5  
modulators. III.

INVENTOR(S): Isaac, Methvin; Slassi, Abdelmalik; Edwards, Louise;  
Xin, Tao; Stefanac, Tomislav

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.

SOURCE: U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070259926	A1	20071108	US 2007-790416	20070425
AR 60813	A1	20080716	AR 2007-101786	20070425
EP 2027110	A2	20090225	EP 2007-761250	20070425
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009536211	T	20091008	JP 2009-509955	20070425
WO 2007130822	A2	20071115	WO 2007-US67369	20070427
WO 2007130822	A3	20080103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2008DN08829	A	20090327	IN 2008-DN8829	20081021



CN 101437813	A	20090520	CN 2007-80016188	20081104
PRIORITY APPLN. INFO.:			US 2006-797665P	P 20060505
			WO 2007-US67369	W 20070427

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S):           MARPAT 147:522248  
 GI



GI





AB The present invention is directed to novel compds. I [R1 = Me, halo or CN; R2 = H or F; R3 = H, F or alkyl; R4 = alkyl, cyclopropyl; X = oxadiazole, tetrazole; Z = (un)substituted 3-pyridyl or 4-pyridyl; R7 = H, F or alkyl], to a process for their preparation, their use in therapy and pharmaceutical compns. comprising the novel compds. Thus, reacting (R)-2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-N-methyl-pyrrolidine-1-carboximidothioic acid Me ester (preparation given) with 2-methylisonicotinic acid hydrazide in iso-PrOH afforded 47% II. Generally, compds. I were active with IC50 values less than 10000 nM in the assay for mGluR5.

IT 956273-92-0P 956273-94-2P 956273-99-7P  
956274-02-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of trisubstituted triazoles as mGluR5 modulators)

RN 956273-92-0 CAPLUS


CN Pyridine, 4-[5-[(2R)-2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 956273-94-2 CAPLUS  
 CN Benzonitrile, 3-[5-[(2R)-1-[4-methyl-5-(3-pyridinyl)-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-2H-tetrazol-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 956273-99-7 CAPLUS  
 CN Benzonitrile, 3-[5-[(2R)-1-[5-(2-methoxy-4-pyridinyl)-4-methyl-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-2H-tetrazol-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 956274-02-5 CAPLUS  
 CN Benzonitrile, 3-[5-[(2R)-1-[4-methyl-5-(2-methyl-4-pyridinyl)-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-2H-tetrazol-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD  
 (6 CITINGS)

L12 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN  
 ACCESSION NUMBER: 2007:1270604 CAPLUS  
 DOCUMENT NUMBER: 147:522247  
 TITLE: Preparation of trisubstituted triazoles as mGluR5 modulators. IV.  
 INVENTOR(S): Isaac, Methvin; Slassi, Abdelmalik; Edwards, Louise; Xin, Tao; Wallberg, Andreas; Stefanac, Tomislav  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.  
 SOURCE: U.S. Pat. Appl. Publ., 18 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070259923	A1	20071108	US 2007-790428	20070425
WO 2007130823	A2	20071115	WO 2007-US67370	20070425
WO 2007130823	A3	20080124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AR 60810	A1	20080716	AR 2007-101783	20070425
EP 2032568	A2	20090311	EP 2007-811854	20070425
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009536212	T	20091008	JP 2009-509956	20070425
IN 2008DN08828	A	20090327	IN 2008-DN8828	20081021
CN 101437815	A	20090520	CN 2007-80016246	20081104
PRIORITY APPLN. INFO.:			US 2006-797662P	P 20060505
			WO 2007-US67370	W 20070425

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT



OTHER SOURCE(S): CASREACT 147:522247; MARPAT 147:522247

GI



II

GI



AB The present invention is directed to novel compds. I [R1 = H or F; R2 = H, F or alkyl; R3 = alkyl or cyclopropyl; X = isoxazole; Z = (un)substituted 3-pyridyl, 4-pyridyl; R6 = H, F or alkyl], to a process for their preparation, their use in therapy and pharmaceutical compns. comprising the novel compds. Thus, reacting 2-[5-(3-cyanophenyl)isoxazol-3-yl]-N-methylpyrrolidine-1-carboximidothioic acid Me ester with 2-methylisonicotinic acid hydrazide in iso-PrOH afforded 55% II. Generally, compds. I were active with IC50 values less than 10000 nM in the assay for mGluR5.


IT 956284-95-0P 956284-97-2P 956284-99-4P  
 956285-00-0P 956285-01-1P 956285-02-2P  
 956285-03-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of trisubstituted triazoles as mGluR5 modulators)


RN 956284-95-0 CAPLUS

CN Benzonitrile, 3-[3-[1-[4-methyl-5-(2-methyl-4-pyridinyl)-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-5-isoxazolyl]- (CA INDEX NAME)




RN 956284-97-2 CAPLUS

CN Benzonitrile, 3-[3-[1-[5-(2-methoxy-4-pyridinyl)-4-methyl-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-5-isoxazolyl]- (CA INDEX NAME)



RN 956284-99-4 CAPLUS


CN Benzonitrile, 3-[3-[1-[4-methyl-5-(3-pyridinyl)-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-5-isoxazolyl]- (CA INDEX NAME)



RN 956285-00-0 CAPLUS

CN Benzonitrile, 3-[3-[(2R)-1-[4-methyl-5-(2-methyl-4-pyridinyl)-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-5-isoxazolyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956285-01-1 CAPLUS

CN Benzonitrile, 3-[3-[(2R)-1-[5-(2-methoxy-4-pyridinyl)-4-methyl-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-5-isoxazolyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956285-02-2 CAPLUS

CN Benzonitrile, 3-[3-[(2R)-1-[4-methyl-5-(3-pyridinyl)-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-5-isoxazolyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956285-03-3 CAPLUS

CN Benzonitrile, 3-[3-[(2R)-1-[4-methyl-5-(4-pyridinyl)-4H-1,2,4-triazol-3-yl]-2-pyrrolidinyl]-5-isoxazolyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)



L12 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN




ACCESSION NUMBER: 2005:962251 CAPLUS  
 DOCUMENT NUMBER: 143:266955  
 TITLE: Synthesis of polyheterocyclic compounds as  
 metabotropic glutamate receptor antagonists  
 INVENTOR(S): Arora, Jalaj; Edwards, Louise; Isaac, Methvin; Kers,  
 Annika; Staaf, Karin; Slassi, Abdelmalik; Stefanac,  
 Tomislav; Wensbo, David; Xin, Tao; Holm, Bjoern  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.  
 SOURCE: PCT Int. Appl., 99 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080386	A1	20050901	WO 2005-US5216	20050217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005214378	A1	20050901	AU 2005-214378	20050217
CA 2555272	A1	20050901	CA 2005-2555272	20050217
EP 1716143	A1	20061102	EP 2005-713792	20050217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1918154	A	20070221	CN 2005-80004339	20050217
BR 2005007481	A	20070717	BR 2005-7481	20050217
JP 2007523181	T	20070816	JP 2006-554235	20050217
SG 149900	A1	20090227	SG 2009-931	20050217
RU 2381226	C2	20100210	RU 2006-127572	20050217
NZ 548693	A	20100528	NZ 2005-548693	20050217
US 20060025414	A1	20060202	US 2005-60561	20050218
AR 47966	A1	20060315	AR 2005-100612	20050218
NO 2006003469	A	20061115	NO 2006-3469	20060728
ZA 2006006314	A	20071227	ZA 2006-6314	20060728
KR 2007052693	A	20070522	KR 2006-7015825	20060804
MX 2006009023	A	20070308	MX 2006-9023	20060808
IN 2006DN04587	A	20070824	IN 2006-DN4587	20060808
US 20070185100	A1	20070809	US 2007-588754	20070202
PRIORITY APPLN. INFO.:			US 2004-545292P	P 20040218
			WO 2005-US5216	W 20050217

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): CASREACT 143:266955; MARPAT 143:266955  
 GI



GI



AB The authors prepared polyheterocyclic compds. I [T = (hetero)aryl; W is attached to C atom on T, W = (R1)m, R1 = OH, halo, NO2, OC1-C6-alkylhalo, C1-C6-alkyl, C2-C6-alkenyl, C1-C6-alkylhalo, C1-C6-alkyl(CO)R5, SO3R5, etc., R5 = H, C1-C6-alkyl, C3-C7-cycloalkyl, aryl, m = 0-4; Y = (R3)p, Z = (R2)n, R2, R3 = OH, C0-C6-alkylcyano, O, NR5, NOR5, halo, OC1-C4-alkyl, etc., n, p = 0-4; X1 = N, NR4, CR4, R4 = H, OH, C1-C6-alkyl, C0-C6-alkylcyano, (SO)C0-C4-alkyl, (SO2)C0-C4-alkyl, etc.; X2 = C, N; X3 = CR4, N, O; X4 = CR4, N, NR4, O; X5 = bond, CR4R8, NR4, O, S, SO, SO2, R8 =

undefined; X6 = CR4, N; X7 = C, N; Q = heterocycloalkyl, heteroaryl] for use in treating mGluR5-mediated disorders such a neurol., psychiatric and gastrointestinal disorders as well as for treating chronic and acute pain disorders. Thus, 4-[(dimethylamino)ethoxy]benzoic acid hydrazide was reacted with piperidinecarboximidothioc acid Me ester II to give triazolylphenoxy di-Me amine III.


IT 863647-37-4P 863647-38-5P 863647-39-6P  
863647-40-9P 863647-41-0P 863647-42-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of polyheterocyclic compds., their metabotropic glutamate receptor antagonist activity, and use in treating mGluR5 mediated disorders)


RN 863647-37-4 CAPLUS

CN Morpholine, 4-[5-[5-[2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-cyclopropyl-4H-1,2,4-triazol-3-yl]-2-pyridinyl]- (CA INDEX NAME)




RN 863647-38-5 CAPLUS


CN Morpholine, 4-[5-[5-[2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]-2-pyridinyl]- (CA INDEX NAME)




RN 863647-39-6 CAPLUS  
 CN Pyridine, 3-[5-[2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 863647-40-9 CAPLUS  
 CN Pyridine, 4-[5-[2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-cyclopropyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 863647-41-0 CAPLUS  
 CN Pyridine, 4-[5-[2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 863647-42-1 CAPLUS  
 CN Pyridine, 3-[5-[2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl]-4-cyclopropyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS  
RECORD (20 CITINGS)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

(FILE 'HOME' ENTERED AT 19:32:56 ON 10 JAN 2011)

FILE 'REGISTRY' ENTERED AT 19:33:14 ON 10 JAN 2011

L1 STRUCTURE UPLOADED  
D  
L2 4 SEA FILE=REGISTRY SSS SAM L1  
L3 STRUCTURE UPLOADED  
D  
L4 50 SEA FILE=REGISTRY SSS SAM L3  
E PYRROLIDINE/CN  
L5 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON PYRROLIDINE/CN  
D STR RSD  
E BENZENE/CN  
L6 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON BENZENE/CN  
D STR RSD  
L7 2020914 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON 46.150.18/RID (P)  
16.136.1/RID  
L8 3 SEA FILE=REGISTRY SUB=L7 SSS SAM L1  
L9 65 SEA FILE=REGISTRY SUB=L7 SSS FUL L1  
L10 64 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L9 AND CAPLUS/LC  
L11 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L9 NOT L10  
D

FILE 'CAPLUS' ENTERED AT 19:36:47 ON 10 JAN 2011

L12 9 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L10  
D L12 IBIB GI ABS HITSTR 1-9

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	54.16	287.65
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.83	-7.83

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 19:37:11 ON 10 JAN 2011